Amgen has announced plans to construct a new multi-product drug substance manufacturing facility in Holly Springs, North Carolina, the US. The company is committed to invest approximately $550m.
Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development. Under terms of
Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.
The US Food and Drug Administration (FDA) has extended the Emergency Use Authorization (EUA) for Regeneron Pharmaceuticals’ investigational Covid-19 antibody cocktail REGEN-COV. Designed to block SARS-CoV-2 infectivity, REGEN-COV
Takeda Pharmaceutical has announced collaboration with Frazier Healthcare Partners to launch HilleVax to develop and commercialise the former’s clinical stage norovirus vaccine candidate, HIL-214 (formerly TAK-214). HIL-214 is
The US Food and Drug Administration (FDA) has extended the Emergency Use Authorization (EUA) for Eli Lilly and Company and Incyte’s baricitinib to treat Covid-19 patients with or
Deep Genomics has raised $180m funding in Series C financing round to expand its artificial intelligence (AI) discovery platform for ‘Programmable’ RNA therapeutics and scale its portfolio into
GlaxoSmithKline (GSK) and Vir Biotechnology have announced a joint procurement agreement with the European Commission for the supply of up to 220,000 doses of sotrovimab to treat Covid-19
AbbVie has extended its collaboration with Calico Life Sciences to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer. The two companies have
Biotechnology company Amgen has agreed to acquire Teneobio, a privately held clinical stage biotechnology firm, in a deal valued at about $900m. Teneobio is developing a new class
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.